Researchers have developed a type of gene therapy that can rescue the function of the TDP-43 protein in diseased nerve cells ...

Differences in human tears in ALS can distinguish bulbar-onset disease from spinal-onset ALS, making this a possible ...

Changes in the production of several immune proteins at the time of an ALS diagnosis were linked to disease progression in ...

Mabylon has received grants from Target ALS and the ALS Association to develop human-derived antibodies to help restore ...

The new patent covers Neurosense's formulation of PrimeC, a fixed-dose combo of an approved antibiotic and anti-inflammatory.

Columnist Juliet Taylor chats with Roon CEO and co-founder Vikram Bhaskaran about this new ALS app designed for patients and ...

The Mayo Clinic was awarded $12 million to support a study that will give ALS patients access to the investigational therapy ...

Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...

The past is always present, we're told, and that's a comfort for columnist Kristin Neva when she can focus on good memories from before ALS.

Neuvivo has filed an application with the U.S. Food and Drug Administration (FDA) requesting the approval of its ...

In an ALS study, growth factor FGF4 reduced the activity of star-shaped cells called astrocytes but did not stop motor ...

Modality.AI and Target ALS are partnering on a clinical study of AI as a way to assess changes in speech and motor function ...